Mechanism of action (eye drops) It is a nucleoside analogue, a modified form of deoxyuridine, similar enough to be incorporated into viral DNA replication, but the –CF3 group added to the uracil component blocks base pairing, thus interfering with viral DNA replication. Pharmacokinetics (eye drops)<unk>  passes the cornea and is found in the aqueous humour. Systemic absorption is negligible. Pharmacokinetics (oral) 5-Trifluoromethyl-2,4(1H,3H)-pyrimidinedione (FTY), the main metabolite Pharmacokinetic data of oral<unk>  have only been evaluated in combination with tipiracil, which significantly affects biotransformation of the former. At least 57% of<unk>  are absorbed from the gut, and highest blood plasma concentrations are reached after two hours in cancer patients. The substance has no tendency to accumulate in the body. Plasma protein binding is over 96%.<unk>  is metabolised by the enzyme thymidine phosphorylase to 5-trifluoromethyl-2,4(1H,3H)-pyrimidinedione (FTY), and also by glucuronidation. Elimination half-life is 1.4 hours on the first day and increases to 2.1 hours on the twelfth day. It is mainly excreted via the kidneys. Tipiracil causes Cmax (highest blood plasma concentrations) of<unk>  to increase 22-fold, and its area under the curve 37-fold, by inhibiting thymidine phosphorylase.
Trifluridine
Decitabine
Apricitabine
Zalcitabine
Nelarabine
Vincristine
Fludarabine
Clofarabine